|
| << vorige | volgende >> |
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
Details van artikel 5 van 6 gevonden artikelen
| Titel: |
Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells |
| Auteur: |
Katerina Kuzelova Dana Grebenova Michaela Pluskalova Iuri Marinov Hana Klamova Zbynek Hrkal |
| Verschenen in: |
Journal of applied biomedicine |
| Paginering: | Jaargang 4 (2006) nr. 2 pagina's 95-104 |
| Jaar: |
2006 |
| Inhoud: |
Tyrosine kinase (TK) activity in primary mononuclear blood cells (MNBC) derived from chronicmyelogenous leukemia (CML) patients in the chronic phase as well as from healthy donors was measuredby a sensitive time-resolved fluorescence method using the Delfia® Tyrosine Kinase kit. The level ofphosphotyrosine was assessed in parallel by flow-cytometry. The experimental protocol for Delfia® wasoptimized using a K562 cell line. A large part (20 to 50%) of the fluorescence signal from K562 cells wassensitive to Imatinib mesylate, an inhibitor of Bcr-Abl tyrosine kinase, which is currently the leadingdrug in CML treatment. In primary MNBC, the direct contribution of Bcr-Abl itself to the signal waslow. However, a 48h treatment of MNBC with 5 μM Imatinib resulted in a significant reduction of theobserved TK activity (mean TK activity value: 56% of control) paralleled by a decrease in thephosphotyrosine level in the CML group. Modification of TK activity by Imatinib was observed also inthe donor group. Imatinib mesylate thus probably affects cell signalization even in Bcr-Abl negative cells. |
| Uitgever: |
University of South Bohemia (provided by DOAJ) |
| Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
Details van artikel 5 van 6 gevonden artikelen
| << vorige | volgende >> |